![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Health Canada Approves Janssen’s Imbruvica for Chronic Lymphocytic Leukemia
Health Canada Approves Janssen’s Imbruvica for Chronic Lymphocytic Leukemia
November 19, 2019
Health Canada approved Janssen’s Imbruvica (ibrutinib) in combination with obinutuzumab for treatment-naïve patients with active chronic lymphocytic leukemia (CLL).
The approval was based on data from a phase 3 clinical trial, in which Imbruvica plus the chemotherapy drug showed a significant improvement in progression-free survival.
The approval is the ninth indication for Imbruvica in Canada, and the first approval for a non-chemotherapy combination regimen for treatment-naïve patients with CLL.
Upcoming Events
-
21Oct